Marbodin

Memantine, the active ingredient in Marbodin, is a NMDA receptor antagonist presented as an oral tablet for oral use. It is used to treat Alzheimer’s disease in adult patients. GNH USA supplies Marbodin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantine acts on the glutamatergic pathway and is indicated for Alzheimer’s disease. - Alzheimer’s disease: helps improve cognition and functional abilities in moderate to severe stages.

Common side effects are generally mild and may resolve with continued therapy.

Common Side Effects: - Dizziness - Headache - Constipation - Confusion

Serious or Rare Side Effects: - Seizures - Severe allergic reactions (rash, swelling, difficulty breathing) - Hallucinations or psychosis - Cardiac arrhythmias

Memantine requires careful consideration in several clinical situations. - Renal impairment: dose adjustment may be necessary. - Hepatic impairment: monitor liver function. - History of seizures: observe for increased seizure activity. - Concomitant NMDA antagonists: avoid combined use. - Pregnancy: safety not established; use only if clearly needed. - Store at room temperature: keep in original container, protect from moisture and light.

Memantine can interact with several drug classes; monitoring is advised.

Major Interactions (Avoid): - Other NMDA antagonists (e.g., amantadine): additive neuro‑blocking effects. - Strong CYP450 inhibitors (e.g., ketoconazole): may increase memantine levels. - Strong CYP450 inducers (e.g., rifampin): may reduce therapeutic effect.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may worsen cognitive symptoms. - CNS depressants (e.g., benzodiazepines): increased sedation risk. - Diuretics: monitor electrolyte balance and renal function.